CTLA4 and adrenal cortex carcinoma: Moreover, CDH13 expression in patients with ACC treated with anti-PD1/CTLA-4, anti-PD1PD-L1, and anti-PD-L1 was significantly downregulated (p = .05) (Figure 4g–i).